Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relugolix single-arm study in women with symptomatic adenomyosis
jRCTs031220684Recruiting
- Start
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of tissue-plasminogen activator in adenomyosis. Primary endpoint: Percent change in uterine volume. Started Mar 2023; status: recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
adenomyosis
Beyond the preview
Go deeper on jRCTs031220684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220684.